ImmunoCellular Therapeutics (IMUC) Tops Q4 EPS by 2c

ImmunoCellular Therapeutics (NYSE: IMUC) reported Q4 EPS of ($0.03), $0.02 better than the analyst estimate of ($0.05).

For earnings history and earnings-related data on ImmunoCellular Therapeutics (IMUC) click here.

You May Also Be Interested In

• Nike (NKE) Tops Q1 EPS by 4c
• Progress Software Corporation (PRGS) Tops Q3 EPS by 17c ; Offers Guidance
• Raymond James sees broad pullback in retail stocks during 3Q26